Developing treatments for the diseases that are hardest to treat*
We wholly own a platform with the potential for treating cancer and selecting patients who would likely benefit from the treatment. Endocyte technology is in mid-stage clinical trials.
PLATFORM YIELDS MULTIPLE NEW SMDCs*
|PROGRAM||INDICATION||PHASE||PRECLINICAL||PHASE 1||PHASE 2||PHASE 3|
|Oncology: Small Molecule Drug Conjugates (SMDCs)|
|EC1169 Prostate-specific Membrane Antigen||Prostate Cancer||PHASE 1|
|Immuno-Oncology: SMDC and Cell-Based Therapy|
|EC2629 FR-expressing Tumor Associated Macrophages + Tumor Cells||Solid Tumors||PRECLINICAL|
|Chimeric Antigen Receptor (CAR) T-Cell (Multiple FITC Adaptor Molecules)||To Be Determined||PRECLINICAL|
|Imaging: Companion Imaging Agents|
|Etarfolatide Folate Receptor||To Be Determined||PHASE 3|
|99mTc -EC0652 Prostate-specific Membrane Antigen||Prostate Cancer||PHASE 1|
Endocyte technology has the potential for broad application
Our technology has the potential to treat the types of cancers found in over 40% of cancer patients worldwide.1
Using our flexible SMDC technology platform, we are also developing precision therapies for other cancer-cell receptors and diseases. One of our imaging agents, EC0652, is being developed to non-invasively identify tumors that overexpress prostate-specific membrane antigen (PSMA) receptors, and is currently being evaluated in a Phase 1 trial for patients with advanced prostate cancer.
An engine for new drug development
With the advent of an innovative form of delivery, more research and development can focus on new potent cytotoxic drugs.
What’s more, our modular technology is being studied with different drugs or a combination of drugs in a variety of diseases, allowing for potential expansion into lower-expressing cancer indications.
Our pipeline and the future of precision medicine
One SMDC is now in a clinical trial and is a prostate-specific membrane antigen (PSMA)-targeted drug. Each targeted therapeutic is also paired with an imaging agent that is designed to identify the patients most likely to benefit from treatment.
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.
1. Reference: Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009 Jun;13(3):256-262. doi: 10.1016/j.cbpa.2009.03.022. Epub 2009 May 4.